Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Author-Supplied Keywords:
      Anatomy
      Arrhythmia
      Atrial fibrillation
      Biochemistry
      Biology and life sciences
      Biomarkers
      Biotechnology
      Blood
      Body fluids
      Cardiology
      Catheters
      Developmental biology
      Endocrine physiology
      Endocrinology
      Fibroblast growth factor
      Fibrosis
      Growth factors
      Mathematical and statistical techniques
      Mathematics
      Medical devices and equipment
      Medicine and health sciences
      Physical sciences
      Physiology
      Regression analysis
      Research and analysis methods
      Research Article
      Statistical methods
      Statistics (mathematics)
    • Abstract:
      Aims: To test the ability of four circulating biomarkers of fibrosis, and of low left atrial voltage, to predict recurrence of atrial fibrillation after catheter ablation. Background: Circulating biomarkers potentially may be used to improve patient selection for atrial fibrillation ablation. Low voltage areas in the left atrium predict arrhythmia recurrence when mapped in sinus rhythm. This study tested type III procollagen N terminal peptide (PIIINP), galectin-3 (gal-3), fibroblast growth factor 23 (FGF-23), and type I collagen C terminal telopeptide (ICTP), and whether low voltage areas in the left atrium predicted atrial fibrillation recurrence, irrespective of the rhythm during mapping. Methods: 92 atrial fibrillation ablation patients were studied. Biomarker levels in peripheral and intra-cardiac blood were measured with enzyme-linked immunosorbent assay. Low voltage (<0.5mV) was expressed as a proportion of the mapped left atrial surface area. Follow-up was one year. The primary endpoint was recurrence of arrhythmia. The secondary endpoint was a composite of recurrence despite two procedures, or after one procedure if no second procedure was undertaken. Results: The biomarkers were not predictive of either endpoint. After multivariate Cox regression analysis, high proportion of low voltage area in the left atrium was found to predict the primary endpoint in sinus rhythm mapping (hazard ratio 4.323, 95% confidence interval 1.337–13.982, p = 0.014) and atrial fibrillation mapping (hazard ratio 5.195, 95% confidence interval 1.032–26.141, p = 0.046). This effect was also apparent for the secondary endpoint. Conclusion: The studied biomarkers do not predict arrhythmia recurrence after catheter ablation. Left atrial voltage is an independent predictor of recurrence, whether the left atrium is mapped in atrial fibrillation or sinus rhythm. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Author Affiliations:
      1Department of Cardiology, Leeds General Infirmary, Leeds, United Kingdom
      2Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom
      3Department of Biomedical Engineering, King’s College, London, United Kingdom
      4Institute of Biomedical Engineering, Karlsruhe Institute of Technology, Karlsruhe, Germany
      5University of Birmingham Institute of Cardiovascular Science, City Hospital, Birmingham, United Kingdom
      6Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
      7School of Biomedical Sciences, University of Leeds, Leeds, United Kingdom
    • Full Text Word Count:
      5574
    • ISSN:
      1932-6203
    • Accession Number:
      10.1371/journal.pone.0189936
    • Accession Number:
      127062078
  • Citations
    • ABNT:
      BEGG, G. A. et al. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. PLoS ONE, [s. l.], v. 13, n. 1, p. 1–13, 2018. DOI 10.1371/journal.pone.0189936. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=127062078&custid=s8280428. Acesso em: 10 ago. 2020.
    • AMA:
      Begg GA, Karim R, Oesterlein T, et al. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. PLoS ONE. 2018;13(1):1-13. doi:10.1371/journal.pone.0189936
    • APA:
      Begg, G. A., Karim, R., Oesterlein, T., Graham, L. N., Hogarth, A. J., Page, S. P., Pepper, C. B., Rhode, K., Lip, G. Y. H., Holden, A. V., Plein, S., & Tayebjee, M. H. (2018). Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. PLoS ONE, 13(1), 1–13. https://doi.org/10.1371/journal.pone.0189936
    • Chicago/Turabian: Author-Date:
      Begg, Gordon A., Rashed Karim, Tobias Oesterlein, Lee N. Graham, Andrew J. Hogarth, Stephen P. Page, Christopher B. Pepper, et al. 2018. “Left Atrial Voltage, Circulating Biomarkers of Fibrosis, and Atrial Fibrillation Ablation. A Prospective Cohort Study.” PLoS ONE 13 (1): 1–13. doi:10.1371/journal.pone.0189936.
    • Harvard:
      Begg, G. A. et al. (2018) ‘Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study’, PLoS ONE, 13(1), pp. 1–13. doi: 10.1371/journal.pone.0189936.
    • Harvard: Australian:
      Begg, GA, Karim, R, Oesterlein, T, Graham, LN, Hogarth, AJ, Page, SP, Pepper, CB, Rhode, K, Lip, GYH, Holden, AV, Plein, S & Tayebjee, MH 2018, ‘Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study’, PLoS ONE, vol. 13, no. 1, pp. 1–13, viewed 10 August 2020, .
    • MLA:
      Begg, Gordon A., et al. “Left Atrial Voltage, Circulating Biomarkers of Fibrosis, and Atrial Fibrillation Ablation. A Prospective Cohort Study.” PLoS ONE, vol. 13, no. 1, Jan. 2018, pp. 1–13. EBSCOhost, doi:10.1371/journal.pone.0189936.
    • Chicago/Turabian: Humanities:
      Begg, Gordon A., Rashed Karim, Tobias Oesterlein, Lee N. Graham, Andrew J. Hogarth, Stephen P. Page, Christopher B. Pepper, et al. “Left Atrial Voltage, Circulating Biomarkers of Fibrosis, and Atrial Fibrillation Ablation. A Prospective Cohort Study.” PLoS ONE 13, no. 1 (January 2, 2018): 1–13. doi:10.1371/journal.pone.0189936.
    • Vancouver/ICMJE:
      Begg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP, et al. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. PLoS ONE [Internet]. 2018 Jan 2 [cited 2020 Aug 10];13(1):1–13. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=127062078&custid=s8280428